Sign In
Buy ATOS
$4.70
-0.150 (-3.09%)
At Close: Jun 03, 2026
Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development Program
01:15pm, Thursday, 16'th Jul 2020
SEATTLE, July 16, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of.
SEATTLE, July 15, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of.
Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on bre
Rexgenero Appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer
12:00am, Thursday, 02'nd Jul 2020
Rexgenero, a regenerative medicine company appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer.
Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com
12:00am, Wednesday, 24'th Jun 2020
The
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
12:00am, Tuesday, 23'rd Jun 2020
The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?
12:05pm, Saturday, 13'th Jun 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201
01:30pm, Thursday, 11'th Jun 2020
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of
Les valeurs à suivre aujourd'hui à la Bourse de Paris Mercredi 10 juin 2020
07:01am, Wednesday, 10'th Jun 2020Celyad devient Celyad Oncology
12:00am, Wednesday, 10'th Jun 2020
Regulatory News: Celyad SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), une société biotechnologique de stade clinique fo
Potential Life Saving COVID-19 Survival Manual Removed from Amazon Kindle Store Three Days before Official Launch
07:49pm, Friday, 05'th Jun 2020
Dr. Steven Quay, MD, PhD, author and physician-scientist, announces the availability of his 158-page book, "Your COVID-19 Survival Manual: A Physician's Guide to Keep You and Your Family Healthy Durin
Atossa Therapeutics: Feeling Bullish About COVID-19 Program (NASDAQ:ATOS)
03:24pm, Tuesday, 02'nd Jun 2020
Atossa Therapeutics has decided to join the COVID-19 effort and is developing two therapeutics, AT-H201, and AT-301. So far, AT-H201 has displayed impressive pr
Dr. Steven Quay, MD, PhD, physician-scientist and CEO of Atossa Therapeutics, Inc. announced today that he and Dr. Martin Lee, PhD, Adjunct Professor of Statistics, UCLA Fielding School of Public Heal
Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on bre
